BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7915094)

  • 1. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
    Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
    Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
    Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
    Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
    Lipponen PK
    J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder.
    Swanson PE; Frierson HF; Wick MR
    Mod Pathol; 1992 Sep; 5(5):531-6. PubMed ID: 1364264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
    Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
    Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
    Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
    Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
    King ED; Matteson J; Jacobs SC; Kyprianou N
    J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.
    Yonemura Y; Ninomiya I; Yamaguchi A; Fushida S; Kimura H; Ohoyama S; Miyazaki I; Endou Y; Tanaka M; Sasaki T
    Cancer Res; 1991 Feb; 51(3):1034-8. PubMed ID: 1670998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of vascular endothelial growth factor in primary superficial bladder cancer.
    Chow NH; Liu HS; Chan SH; Cheng HL; Tzai TS
    Anticancer Res; 1999; 19(5C):4593-7. PubMed ID: 10650816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.